1. Home
  2. JNVR vs ENSC Comparison

JNVR vs ENSC Comparison

Compare JNVR & ENSC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • JNVR
  • ENSC
  • Stock Information
  • Founded
  • JNVR 2018
  • ENSC 2003
  • Country
  • JNVR United States
  • ENSC United States
  • Employees
  • JNVR N/A
  • ENSC N/A
  • Industry
  • JNVR Finance: Consumer Services
  • ENSC Biotechnology: Pharmaceutical Preparations
  • Sector
  • JNVR Finance
  • ENSC Health Care
  • Exchange
  • JNVR Nasdaq
  • ENSC Nasdaq
  • Market Cap
  • JNVR 7.3M
  • ENSC 9.0M
  • IPO Year
  • JNVR 2023
  • ENSC N/A
  • Fundamental
  • Price
  • JNVR $5.49
  • ENSC $6.06
  • Analyst Decision
  • JNVR
  • ENSC
  • Analyst Count
  • JNVR 0
  • ENSC 0
  • Target Price
  • JNVR N/A
  • ENSC N/A
  • AVG Volume (30 Days)
  • JNVR 19.3K
  • ENSC 62.4K
  • Earning Date
  • JNVR 03-27-2025
  • ENSC 03-14-2025
  • Dividend Yield
  • JNVR N/A
  • ENSC N/A
  • EPS Growth
  • JNVR N/A
  • ENSC N/A
  • EPS
  • JNVR N/A
  • ENSC N/A
  • Revenue
  • JNVR $1,820,969.00
  • ENSC $4,421,404.00
  • Revenue This Year
  • JNVR N/A
  • ENSC $89.78
  • Revenue Next Year
  • JNVR N/A
  • ENSC N/A
  • P/E Ratio
  • JNVR N/A
  • ENSC N/A
  • Revenue Growth
  • JNVR N/A
  • ENSC 40.41
  • 52 Week Low
  • JNVR $3.37
  • ENSC $2.12
  • 52 Week High
  • JNVR $11.84
  • ENSC $21.00
  • Technical
  • Relative Strength Index (RSI)
  • JNVR 52.35
  • ENSC 39.92
  • Support Level
  • JNVR $4.88
  • ENSC $6.61
  • Resistance Level
  • JNVR $5.59
  • ENSC $7.36
  • Average True Range (ATR)
  • JNVR 0.64
  • ENSC 0.65
  • MACD
  • JNVR -0.02
  • ENSC -0.13
  • Stochastic Oscillator
  • JNVR 33.70
  • ENSC 6.32

About JNVR Janover Inc.

Janover Inc is a B2B fintech marketplace providing a platform for commercial property borrowers and lenders. It provides a technology platform that connects commercial mortgage borrowers looking for debt to refinance, build, or buy commercial property including apartment buildings to commercial property lenders including banks, credit unions, REITs, debt funds, and more looking to deploy capital into commercial mortgages. The firm caters to two consumer segments: lenders and borrowers. It derives the majority of its revenue from transaction fees.

About ENSC Ensysce Biosciences Inc.

Ensysce Biosciences Inc is a clinical-stage biotech company using its proprietary technology platforms to develop safer prescription drugs. The company is developing a new class of powerful, tamper-proof opioids that prevent both drug abuse and overdoses. Its products are anticipated to provide safer options to treat severe pain and assist in preventing deaths caused by opioid abuse, reducing human and economic costs. The company's current development pipeline includes two new drug platforms: an abuse-resistant opioid prodrug technology, the Trypsin Activated Abuse Protection, or the TAAP platform, and an over-dose protection opioid prodrug technology, the Multi-Pill Abuse Resistant, or the MPAR platform. The Company currently operates in one business segment, which is pharmaceuticals.

Share on Social Networks: